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Impact of an Antimicrobial Utilization Program on Antimicrobial
Use at a Large Teaching Hospital: A Randomized Controlled Trial
Bernard C. Camins, MD, MSc; Mark D. King, MD, MSc; Jane B. Wells, PharmD; Heidi L. Googe, PharmD;
Manish Patel, PharmD; Ekaterina V. Kourbatova, MD, PhD, MPH; Henry M. Blumberg, MD
background. Multidisciplinary antimicrobial utilization teams (AUTs) have been proposed as a mechanism for improving antimicrobial
use, but data on their efficacy remain limited.
objective. To determine the impact of an AUT on antimicrobial use at a teaching hospital.
design. Randomized controlled intervention trial.
setting. A 953-bed, public, university-affiliated, urban teaching hospital.
patients. Patients who were given selected antimicrobial agents (piperacillin-tazobactam, levofloxacin, or vancomycin) by internal
medicine ward teams.
intervention. Twelve internal medicine teams were randomly assigned monthly: 6 teams to an intervention group (academic detailing
by the AUT) and 6 teams to a control group that was given indication-based guidelines for prescription of broad-spectrum antimicrobials
(standard of care), during a 10-month study period.
measurements. Proportion of appropriate empirical, definitive (therapeutic), and end (overall) antimicrobial usage.
results. A total of 784 new prescriptions of piperacillin-tazobactam, levofloxacin, and vancomycin were reviewed. The proportion of
antimicrobial prescriptions written by the intervention teams that was considered to be appropriate was significantly higher than the
proportion of antimicrobial prescriptions written by the control teams that was considered to be appropriate: 82% versus 73% for empirical
(risk ratio [RR], 1.14; 95% confidence interval [CI], 1.04–1.24), 82% versus 43% for definitive (RR, 1.89; 95% CI, 1.53–2.33), and 94%
versus 70% for end antimicrobial usage (RR, 1.34; 95% CI, 1.25–1.43). In multivariate analysis, teams that received feedback from the
AUT alone (adjusted RR, 1.37; 95% CI, 1.27–1.48) or from both the AUT and the infectious diseases consultation service (adjusted RR,
2.28; 95% CI, 1.64–3.19) were significantly more likely to prescribe end antimicrobial usage appropriately, compared with control teams.
conclusions. A multidisciplinary AUT that provides feedback to prescribing physicians was an effective method in improving anti-
microbial use.
trial registration. ClinicalTrials.gov identifier: NCT00552838.
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The worldwide emergence of antimicrobial resistance is a
major public health problem and substantially impacts patient
treatment and outcomes.1 Antimicrobial resistance continues
to increase among bacteria that cause disease in both com-
munity and hospital settings.2-5 The relationship between an-
timicrobial use and antimicrobial resistance is complex, but
a growing body of data strongly suggests that higher levels
of antimicrobial usage are associated with higher levels of
antimicrobial resistance.6-9 The persistent increase in anti-
microbial resistance has created concern that we are enter-
ing a “post–antibiotic era,” in which some bacterial infec-
tions will no longer be treatable.10,11
Antimicrobial use in hospitalized patients is common, with
patients in the intensive care units receiving antibiotics on 70%
of their intensive care unit–days and patients on the general
inpatient wards receiving antibiotics on at least 40% of their
inpatient-days.12 Studies have documented that up to 50%
of all in-hospital antimicrobial use is inappropriate.13,14 The
inappropriate use of antimicrobials represents an important
patient safety issue, because inappropriate use may be associ-
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ated with adverse patient outcomes, increased cost of medi-
cal care, and increased antimicrobial resistance among noso-
comial pathogens.1
Various approaches, including physician education, hospi-
tal formulary restriction of antimicrobials, required approv-
al of selected antimicrobials, antimicrobial prescribing guide-
lines, computer-assisted antimicrobial prescribing, and antimi-
crobial order forms, have been undertaken in an attempt to
reduce inappropriate antimicrobial use. However, it remains
unclear which approaches are effective and whether these mea-
sures are sustainable.15-22 Multidisciplinary antimicrobial util-
ization teams (AUTs) that include clinicians (eg, infectious
diseases [ID] physicians) as well as pharmacy and microbi-
ology personnel are thought to be an important mechanism
for improving antimicrobial use, but data remain limited with
regard to the impact of such an approach on the reduction
of inappropriate antimicrobial usage and antimicrobial resis-
tance.17,23-26 There have been few randomized trials that eval-
uate methods to improve antimicrobial usage.19,20,22 To better
define the role of a multidisciplinary AUT in the improve-
ment of antimicrobial use, we conducted a randomized con-
trolled trial to determine the efficacy of a multidisciplinary
AUT, compared with the efficacy of indication-based anti-
microbial prescribing guidelines (standard of care at our in-
stitution), in optimizing antimicrobial use at a large univer-
sity-affiliated public hospital.
methods
Study Design and Setting
We conducted a randomized controlled trial to compare the
efficacy of a multidisciplinary AUT with that of indication-
based antimicrobial prescribing guidelines in optimizing use
of 3 antimicrobial agents by the internal medicine services at
Grady Memorial Hospital (Atlanta, Georgia). The study was
approved by the Emory University Institutional Review Board
and the Grady Research Oversight Committee. Grady Me-
morial Hospital is a 953-bed, urban, public teaching hospital
affiliated with Emory University School of Medicine. Twelve
internal medicine teams that are staffed by physicians from
Emory University and that treat inpatients at Grady Memorial
Hospital and function independently of one another were
included. Each of the 12 internal medicine teams consisted
of a faculty attending physician, a senior resident (postgrad-
uate year 3), 2 junior residents (postgraduate year 1), and 1
or 2 medical students. Physicians may rotate on the internal
medicine service more than once during the year and may
be assigned to a different team on different months. The
internal medicine teams care for patients on the general med-
ical wards and step-down units but not on the medical in-
tensive care unit.
The teams were randomly assigned to 1 of 2 antimicrobial
utilization strategies during the 10-month period October
2002–July 2003: (1) interaction with a multidisciplinary AUT
(intervention group) or (2) indication-based antimicrobial
prescribing guidelines that represented the standard of care
(control group). Each month, 6 internal medicine teams were
randomly assigned to the intervention arm and 6 teams were
randomly assigned to the control group by means of a ran-
dom number list. The AUT consisted of an ID physician
(faculty member M.D.K.) and an ID clinical pharmacist
(PharmD) who worked closely with microbiology person-
nel for acquisition of clinical microbiology results. The AUT
provided structured feedback to prescribing physicians on
the appropriateness of antimicrobial use. Structured verbal
feedback consisted of either a short phone conversation or a
face-to-face meeting on the indication for which the anti-
microbial was being prescribed and a recommendation for a
more optimal antimicrobial choice (as defined by hospital
criteria for appropriate antimicrobial use [Appendix]).
All medical teams, regardless of randomization allocation,
received at the start of each month pocket-sized cards that
contained the Grady Memorial Hospital guidelines for use of
antimicrobial agents, including guidelines for the use of the
targeted study drugs: piperacillin-tazobactam, vancomycin, and
levofloxacin. The AUT received a daily list from the pharmacy
of all new orders for piperacillin-tazobactam, vancomycin, and
levofloxacin. The medical records (including charts, pharmacy
records, and laboratory results) of patients who were examined
by the 12 teams and who received one of these antimicrobials
were reviewed by an AUT clinical pharmacist (J.B.W., H.L.G.,
or M.P.) and/or the ID fellow (B.C.C.). Each medical record
was reviewed individually by one of the reviewers. Only one
reviewer was needed to review charts each day. Data were
collected using standardized report forms. A daily audit of
microbiologic data, including results of cultures of blood,
sputum, and urine samples and drug susceptibility profiles
of causative organisms, was conducted for patients who were
receiving piperacillin-tazobactam, vancomycin, and levoflox-
acin. These antimicrobials were chosen on the basis of pre-
vious data that showed particularly high use of these drugs
at our institution when benchmarked against use at other
institutions.
Each antimicrobial prescription was reviewed to determine
whether the criteria for appropriate antimicrobial use were
met. The criteria used to define “appropriate” antimicrobial
use are outlined in the Appendix. For patients receiving more
than one of these antimicrobial agents, an independent as-
sessment of use was made for each drug. The assessment of
appropriateness of use was made by the director of the AUT
(M.D.K.) on the basis of a verbal report from the reviewer
and data from the standardized report form. The AUT di-
rector was blinded to team allocation (intervention or con-
trol) to prevent bias when determining whether criteria for
optimal use were met.
If the antimicrobial use did not meet the criteria for “ap-
propriate” use, the AUT director made recommendations for
alternative antimicrobial therapy; if the prescription was writ-
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table 1. Baseline Characteristics of Patients Who Had Antimi-
crobials Prescribed by Physicians on Internal Medicine Teams in the











Male 175 (45) 205 (52) .04
Female 212 (55) 186 (47)
Age, mean (range), years 54 (3–97) 54 (2–99) .59
Race
Black 305 (78) 331 (84) .04b
White 35 (9) 21 (5)
Hispanic 10 (3) 6 (2)
Other 5 (1) 2 (1)
Unknown 33 (9) 30 (8)
Most common diagnoses
Pneumonia 63 (16) 67 (17) .75
Bloodstream infection 37 (9) 20 (5) .02
Complicated UTI 60 (15) 50 (13) .28
Uncomplicated UTI 20 (5) 12 (3) .14
Asymptomatic bacteriuria 10 (3) 24 (6) .02
note. Data are no. (%) of prescriptions, unless indicated otherwise. UTI,
urinary tract infection.
a Data on sex were available for 387 patients in the intervention group and
392 patients in the control group.
b Black versus all other races combined.
ten by a physician on one of the teams randomly assigned to
the intervention, then the recommendations were communi-
cated to the prescribing physician by one of the PharmDs or
the ID fellow. Recommendations were not communicated to
the control group unless failure to do so could seriously jeop-
ardize the patient (eg, use of an antibiotic without in vitro
activity against the isolated pathogen, which occurred in less
than 1% of the control group prescriptions). In complicated
cases, the AUT recommended that the intervention group seek
advice from the ID consult service. Intervention and control
teams were not informed that the study was taking place.
Definitions
Initial antimicrobial use (within 72 hours of starting therapy)
was defined as any antimicrobial treatment initiated for em-
pirical coverage while microbiologic results were pending or
for definitive therapy in which a pathogen was already known.
Empirical antimicrobial use was defined as antimicrobial use
that occurred within 72 hours of initiation of therapy while
microbiologic culture results were pending or antimicrobial
use in situations after 72 hours of initiation when microbi-
ologic cultures did not yield a pathogen.
Definitive (therapeutic) antimicrobial use was defined as
any antimicrobial use at a time when microbiologic culture
results and susceptibility data were available. This could have
occurred at initiation of therapy or after empirical antimi-
crobial use was initiated once microbiologic culture results
were available.
End antimicrobial use was defined as the final choice of
antimicrobial regimen selected for the indication being treated.
This category includes definitive antimicrobial use in which a
pathogen was isolated or empirical antimicrobial use in which
no pathogen was ever isolated or for which microbiologic cul-
tures were never obtained.
Study Outcomes
The primary outcomes included (1) the proportion of pre-
scriptions for empirical therapy that was appropriate, (2) the
proportion of prescriptions for definitive therapy that was
appropriate, and (3) the proportion of end antimicrobial us-
age that was appropriate. Secondary end points included (1)
the volume of inappropriate antimicrobial use in defined daily
doses (DDDs),27 (2) the duration of inappropriate antimi-
crobial use in days, (3) the hospital length of stay, and (4)
the clinical outcome of in-hospital mortality. The primary
and secondary outcomes were focused on antimicrobial us-
age measures with comparisons between the control and in-
tervention groups.
Statistical Analysis
Sample size calculations. Assuming a baseline proportion of
inappropriate use for target antimicrobials of 35% (with in-
appropriate use data based on preliminary usage data from
Grady Memorial Hospital), review of at least 330 antimicro-
bial prescriptions in each arm would allow for detection of
a 10% reduction in inappropriate antimicrobial use at ap
and ..05 bp 0.80
Data analysis. Data analyses were performed using SAS
software, version 9.1 (SAS Institute). Baseline data for the
intervention and control groups were assessed at the ran-
domization unit level (internal medicine team), with aggre-
gation of the data according to randomization units. The unit
of analysis was on the level of prescriptions written for each
of the targeted drugs. Risk ratios (RRs), 95% confidence in-
tervals (CIs), and P values for the intervention effect on cat-
egorical outcomes were estimated with univariate log-bino-
mial regression models. Continuous variables were compared
using a 2-sample t test or Wilcoxon rank-sum test. Variables
associated with appropriate end antimicrobial usage were ini-
tially assessed by univariate analysis. Multivariate analysis was
performed using a multiple log-binomial regression model
to control for confounding and effect modification; we took
into account the hierarchy principle. Two-way interactions
between the intervention status variable and probable effect
modifiers were examined (significant interaction was found
between intervention status and ID consultations). Con-
founding assessment following by precision considerations
was performed. Backward selection model building was used
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Antibiotic use deemed appropriate
Initial (!72 hours) 305/390 (78) 229/394 (58) 1.35 (1.22–1.49) !.001
Empirical 242/294 (82) 211/291 (73) 1.14 (1.04–1.24) .005
Definitive 92/112 (82) 60/138 (43) 1.89 (1.53–2.33) !.001
Appropriate cultures obtained 188/270 (70) 193/286 (67) 1.03 (0.92–1.15) .59
Changed to recommended antibioticsa 168/186 (90) 85/199 (43) 2.11 (1.79–2.50) !.001
Appropriate end antimicrobial usage 367/390 (94) 277/394 (70) 1.34 (1.25–1.43) !.001
note. CI, confidence interval.
a In the control group, a blinded assessment of the appropriateness of the antimicrobial therapy was still made
by the medical director of the antimicrobial utilization program. However, any recommendations for optimization
of therapy were only recorded and never conveyed to the control group physicians.






Duration of inappropriate use, median (range), days 2.0 (1–16) 5.0 (1–20) !.001
Total volume of inappropriate use, DDDs 441 753
Median volume of inappropriate use (range), DDDs 2.0 (0.5–16) 4.0 (0.3–16.5) !.001
note. DDD, daily defined dose.
a Wilcoxon 2-sample test.
to arrive at the final model. A P value of .05 or less was
considered to be statistically significant.
results
A total of 784 new prescriptions were reviewed by the AUT
during the 10-month study period; this included 440 (56%)
for levofloxacin, 162 (21%) for piperacillin-tazobactam, and
182 (23%) for vancomycin. Demographic and clinical char-
acteristics of the patients prescribed these antimicrobial agents
are listed in Table 1. Initial antimicrobial use (within the first
72 hours of patient receipt) as well as empirical and definitive
antimicrobial use were all significantly more likely to be ap-
propriate among patients cared for by intervention teams, com-
pared with those cared for by control teams (Table 2). Overall,
367 (94%) of 390 prescriptions that represented end antimi-
crobial usage among the intervention group were appropriate,
compared with 277 (70%) of 394 prescriptions that represented
end antimicrobial usage among the control group (RR, 1.34;
95% CI, 1.25–1.43). Among inappropriate end antimicrobial
usage, 107 (42%) of 253 prescriptions were related to use of
an antimicrobial agent when none was indicated or necessary
and 144 (57%) of 253 prescriptions were related to use of an
antimicrobial agent considered to be inappropriate by the hos-
pital’s antibiotic use guidelines (Appendix).
Internal medicine teams randomly assigned to the inter-
vention group had a significantly shorter median duration of
inappropriate use (2.0 days/prescription vs 5.0 days/prescrip-
tion; ) and lower median DDDs of inappropriate an-P ! .001
timicrobial use (2.0 vs 4.0 DDDs; ), compared withP ! .001
teams randomly assigned to the control group (Table 3).
There were no differences in the in-hospital mortality rates
among patients cared for by the intervention teams (11 [3%]
of 390 patients died) or control teams (18 [5%] of 394 pa-
tients died) ( ). Patients treated by the interventionPp .18
group also had a shorter median length of stay (7 days [range,
1–50 days]), compared with patients treated by the control
group (8 days [range, 2–86 days]) ( ). An ID consultPp .03
was obtained by the primary internal medicine team in only
63 (8%) of 773 episodes with available information in which
an antimicrobial agent was prescribed (34 [8.8%] of 386 ep-
isodes for intervention teams vs 29 [7.5%] of 387 episodes
for control teams; ).Pp .50
In univariate analysis, factors associated with appropriate
end antimicrobial usage included intervention by the AUT
(RR, 1.34; 95% CI, 1.25–1.43), consultation with the ID ser-
vice (RR, 1.15; 95% CI, 1.07–1.24), and an abnormal finding
present on chest radiograph (RR, 1.13; 95% CI, 1.02–1.24)
(Table 4). In multivariate analysis, independent predictors for
appropriate end antimicrobial usage included AUT interven-
tion and ID consultation; we found significant interaction
between these 2 factors. The highest effect on appropriate
end antimicrobial usage included AUT intervention com-
bined with ID consultation (adjusted RR [aRR], 2.28; 95%
CI, 1.64–3.19). AUT intervention without ID consultation
impact of an aut on antimicrobial use 935
table 4. Univariate and Multivariate Analysis of Predictors for Appropriate End Antimicrobial Use for 784 Prescriptions
Variable








!50 years old 307 (48) 59 (42) 1.04 (0.97–1.11) .23 …
Male sex 318/641 (50) 62/137 (45) 1.03 (0.97–1.10) .35 …
Black race 524 (81) 112 (80) 1.02 (0.93–1.11) .71 …
LOS !8 days 322 (50) 69 (49) 1.01 (0.94–1.07) .88 …
Abnormal chest radiograph finding 199/314 (63) 25/56 (45) 1.13 (1.02–1.24) .01 …
Prescriber associated
AUT intervention 367 (57) 23 (16) 1.34 (1.25–1.43) !.001
With ID consultation … … … 2.28 (1.64–3.19) !.001
Without ID consultation … … … 1.37 (1.27–1.48) !.001
ID consultation (alone) 59/635 (9) 4/138 (3) 1.15 (1.07–1.24) !.001 1.31 (1.14–1.51) !.001
PGY 11 year 211/605 (35) 40/130 (31) 1.03 (0.96–1.11) .36 …
note. Data are no. (%) or proportion (%) of prescriptions, unless otherwise indicated. Data were missing for some patients. AUT, antimicrobial
utilization team; CI, confidence interval; ID, infectious diseases; LOS, length of stay; PGY, postgraduate year; RR, risk ratio.
table 5. Summary of Randomized Controlled Trials on Antimicrobial Utilization Team (AUT) Interventions to Improve Antibiotic
Prescribing Practices for Hospital Inpatients
Author, publication year Sample size Intervention Primary outcome
Fraser et al [19], 1997 252 patients AUT (ID fellow and a clinical
pharmacist)
Per patient antibiotic charges decreased in the intervention
group, compared with the control group. Clinical and mi-
crobiological response, antibiotic-associated toxic effects,
in-hospital mortality, and readmission rates were similar
for both groups.
Solomon et al [20], 2001 278 antimicrobial
prescriptions
Academic detailing (clinician ed-
ucators, ID physicians, and
specially trained clinical
pharmacist)
Number of days that unnecessary levofloxacin or ceftazidime
was used was reduced by 37% in intervention group, com-
pared with the control group. In the intervention group,
70% of unnecessary orders were discontinued; in the con-
trol group, 30%.
Dranitsaris et al [22], 2001 323 antimicrobial
prescriptions
Educational intervention (clini-
cal pharmacist without ID
faculty support)
Appropriateness of cefotaxime use did not improve.
Camins et al, 2009 (PR) 784 antimicrobial
prescriptions
AUT (ID physician faculty
member, clinical pharmacist
[PharmD])
Proportion of appropriate antimicrobial prescriptions in-
creased: 78% vs 58% for empirical usage (RR, 1.35), 82%
vs 43% for definitive usage (RR, 1.89), and 94% vs 70%
for end antimicrobial usage (RR, 1.34).
note. All 4 studies were performed in the United States. ID, infectious diseases; PR, present report; RR, risk ratio.
(aRR, 1.37; 95% CI, 1.27–1.48) and ID consultation without
AUT intervention (aRR, 1.31; 95% CI, 1.14–1.51) also in-
dependently predicted appropriate end antimicrobial usage
in multivariate analysis (Table 4).
discussion
In this randomized controlled trial, we found that physicians
on teams randomly assigned to the intervention group (who
received structured feedback from the AUT) were significantly
more likely to use antimicrobials appropriately than physi-
cians on teams randomly assigned to the control group (who
were given cards with guidelines for appropriate antimicrobial
use but who received no feedback from the AUT). Feedback
from the AUT resulted in a significantly higher proportion
of initial antimicrobial therapy deemed appropriate in the
intervention group, compared with the control group (78%
vs 58%; RR, 1.35), as well as a higher proportion of end
antimicrobial use deemed appropriate: 367 (94%) of 390 an-
timicrobials prescribed by the intervention group were ap-
propriate, compared with only 277 (70%) of 394 antimicro-
bials prescribed by the control group (RR, 1.34). Patients
treated by the intervention teams had a significantly shorter
median length of stay, compared with patients treated by the
control teams. In-hospital mortality rates were low in both
arms and did not differ significantly between the 2 groups.
We found that receiving feedback from both the AUT and
the ID consult service was associated with the highest like-
lihood of appropriate end antimicrobial usage (aRR, 2.28,
compared with the control group). The AUT intervention
alone (intervention group) or an ID consult alone (control
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group) was also associated with significantly higher appro-
priate antimicrobial use, compared with no feedback at all.
In our study, an ID consult was obtained in only 8% of all
antimicrobial prescriptions (and this did not significantly dif-
fer between intervention and control teams). The vast ma-
jority of antimicrobial prescriptions are written without ID
service consultation; therefore, having an AUT to provide
feedback on antimicrobial use is important. Furthermore, our
data indicated that there was an additive or synergistic effect
when there was involvement of both the ID consult service
and AUT feedback. In such cases, the likelihood that the
antimicrobial prescription was appropriate increased by a fac-
tor of nearly 2.
Data on how best to improve antimicrobial use, including
data from randomized controlled trials that assess the impact
and efficacy of a multidisciplinary AUT in improving anti-
microbial use in the hospital setting,19,20 are limited. Much of
what has been published are data from smaller studies that
were performed for short periods, that used historical con-
trols, or that were not randomized.19-22,25-27 Table 5 summa-
rizes previous randomized trials on the impact and efficacy
of an AUT. Our randomized controlled trial, which was per-
formed during a 10-month period, is the longest randomized
study reported to date and has the largest number of pre-
scriptions of antibiotics ( ) included in the analysis.np 784
To our knowledge, our study is only the second study in the
hospital setting that randomly assigned groups of treating
physicians, as opposed to antimicrobial prescriptions. The
previous studies randomly assigned treatment groups by an-
timicrobial prescriptions or patients, so all treating physicians
may have been exposed to the daily academic detailing in-
tervention; this exposure could have increased bias through
cross-contamination.19,20,22 To further decrease bias in our
study, the assessment of the appropriateness of therapy was
performed in a blinded fashion (ie, the AUT director was
blinded to the randomization group allocation of each pre-
scription reviewed; feedback was provided to physicians on
the intervention teams by a PharmD or ID fellow). Similar
to previous studies, the appropriateness of antimicrobial use
in this study was determined on the basis of hospital guide-
lines approved by the hospital pharmacy and therapeutics
committee. These guidelines were developed after a review
of national guidelines and evidence-based medical literature.
Our study has several limitations. First, we could not com-
pletely remove the potential for cross-contamination between
the intervention and control groups during the trial. Physi-
cians could spend more than one month on the internal
medicine team, so some may have been on an intervention
team one month and a control team another month. How-
ever, this would have biased the findings to the null hypothesis
(ie, no difference between control and intervention groups).
Another limitation was that this study was conducted among
internal medicine ward teams and did not include teams
working in intensive care units and on other medical sub-
specialties (such as the surgical services). Because there is
only a single large medical intensive care unit team, it was
not feasible to include that group. Because the target group
of physicians included in this study were only those in internal
medicine and because this study was carried out at a uni-
versity-affiliated teaching hospital, care should be exercised
in generalizing these results to other settings. In the control
group, twice as many patients were given antibiotics for
asymptomatic bacteriuria, compared with the intervention
group ( ), which may potentially create bias away fromPp .02
the null in results. Finally, we were unable to measure the
effect that our intervention had on the development of an-
timicrobial resistance in our hospital.
conclusions
In a randomized controlled trial, structured feedback pro-
vided by a multidisciplinary AUT proved to be an effective
method of improving antimicrobial use in a teaching hospi-
tal. This improvement was seen in the entire antimicrobial
prescribing process, from empirical prescriptions to end an-
timicrobial use after microbiological results were available.
In multivariate analysis, independent predictors for appro-
priate end antimicrobial use were the AUT intervention and
consultation with an ID specialist. Future studies should also
examine the sustainability of the impact of such a team on
other medical subspecialties and for periods longer than 10
months as well as the impact on the rates of drug resistance,
including multidrug resistance, of isolates.
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Recommendations were made with the goal of modifying
antimicrobial therapy such that all criteria for optimal use
were met. For any antimicrobial use to be deemed appro-
priate, it had to satisfy the following criteria: (1) the anti-
microbial prescribed for the indication met hospital guide-
lines, (2) the antimicrobial prescribed had activity against the
suspected or recovered pathogen, (3) the dose of the anti-
microbial prescribed was adjusted in cases of renal or hepatic
impairment, (4) the antimicrobial therapy was necessary, and
(5) the patient had no known allergy to the antimicrobial
prescribed. In addition, dose and duration of therapy were
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table A1. Grady Memorial Hospital Guidelines for Appropriate Use of Levofloxacin, Piperacillin-Tazobactam, and Vancomycin During
the Study Period
Piperacillin-tazobactam
A. Severe diabetic skin and soft-tissue infections (eg, toxic-appearing patient who requires surgical debridement or polymicrobial iso-
late with high suspicion of infection with Pseudomonas aeruginosa)
B. Empirical use for suspected nosocomial infections that include sepsis, intra-abdominal infection, and nosocomial pneumonia for
72 hours pending culture and susceptibility results
C. Treatment of nosocomial infections due to:
1. Organisms resistant to first- and second-generation cephalosporins or piperacillin
2. Mixed infections involving aerobic and anaerobic organisms
Levofloxacin (intravenous and oral)
A. Empirical therapy
1. Pyelonephritis and/or complicated urinary tract infection
2. Gastrointestinal infection likely due to Salmonella, Shigella, or Campylobacter spp
3. Nosocomial gram-negative infections. Continued use beyond 72 hours with negative culture results or use when the organism
isolated is susceptible to a first- and/or second-generation cephalosporin requires approval from the ID service.a
4. Presumed treatment of “atypical” pneumonia (due to Legionella spp, Mycoplasma pneumoniae, or Chlamydia pneumoniae)
5. Single dose for genitourinary surgical prophylaxis in high-risk patients (urine culture results positive or unavailable, preoperative
catheter, and/or transrectal prostatic biopsy)
B. Treatment of:
1. Pyelonephritis/complicated urinary tract infection in patients with pathogens resistant to first- and second-generation
cephalosporins
2. Prostatitis for patients intolerant or refractory to trimethoprim/sulfamethoxazole
3. Infections due to gram-negative organisms that are resistant to first- and second-generation cephalosporins
4. Mycobacterial infections
a. Multidrug-resistant tuberculosis
b. Parenteral therapy for tuberculosis
c. Other mycobacterial infections
5. Susceptible Pseudomonas and Enterobacter spp infections
6. Gram-negative infections in patients with a history of an allergy to b-lactam antibiotics
7. Gastrointestinal infections
a. Due to Salmonella or Shigella spp resistant to trimethoprim-sulfamethoxazole
b. Due to Salmonella or Shigella in patients allergic to trimethoprim-sulfamethoxazole
c. Due to Campylobacter spp
8. Osteomyelitis
Vancomycin (intravenous)
A. Empirical criteria (for 72 hours pending culture and susceptibility results)
1. When there is a high suspicion of methicillin-resistant Staphylococcus aureus (MRSA) or coagulase-negative Staphylococcus infec-
tion with pending culture and susceptibility results
2. Suspected pneumococcal meningitis
3. Suspicion of life-threatening infection in children (eg, fulminant sepsis in sickle-cell patient)
B. Treatment criteria
1. For documented infections where the organism is not susceptible to alternative antibiotics (ie, for use in the treatment of methi-
cillin-resistant staphylococcal infections [MRSA], coagulase-negative Staphylococcus, or ampicillin-resistant enterococcal
infections)
2. The patient has a documented, severe allergy to b-lactam antibiotics (eg, among patients with a methicillin-susceptible staphylo-
coccal infection)
3. Pneumococcal meningitis resistant to b-lactam antibiotics (eg, penicillin or third- generation cephalosporin)
note. ID, infectious diseases.
a P. aeruginosa susceptibility to levofloxacin during the study was approximately 70%.
reviewed; however, these 2 measures were not included as cri-
teria for appropriate use. The hospital guidelines for each of
the antimicrobials included in the study are listed in Table A1.
Types of recommendations made to the prescribing physi-
cian and internal medicine team included the following: (1)
modification in antimicrobial choice to meet the hospital pre-
scribing guidelines, (2) modification in antimicrobial choice to
provide active spectrum against the suspected or isolated path-
ogen, (3) modification in dose to adjust for renal or hepatic
insufficiency, (4) discontinuation of antimicrobial therapy for
unnecessary use, and (5) modification in antimicrobial choice
for patients with known allergies to prescribed antimicrobial
938 infection control and hospital epidemiology october 2009, vol. 30, no. 10
or potential cross-reactivity between prescribed antimicrobial
and known allergy (eg, cephalosporin use for a patient with a
serious penicillin allergy such as anaphylaxis).
For definitive (therapeutic) use (ie, microbiologically de-
fined etiology), additional recommendations included the fol-
lowing: (1) modification of the antimicrobial choice to pro-
vide targeted antimicrobial therapy (streamlining) on the basis
of culture and susceptibility results (eg, to an equally efficacious
agent that may have a more narrow spectrum of activity and
may be less expensive) and (2) modification of duration of
therapy in accordance with evidence-based guidelines. The
AUT director remained blinded to team allocation during the
recommendation process. These recommendations were re-
corded on the case report form for both the control and the
intervention groups. Inappropriate antimicrobial use was clas-
sified into 3 categories: (1) antimicrobial use that was unnec-
essary (eg, treatment of asymptomatic bacteriuria or use of an
antimicrobial agent for patients who had colonization but no
infection), (2) antimicrobial prescribed that was inconsistent
with the hospital’s indication-based guidelines (eg, prescribing
piperacillin-tazobactam for treatment of community-acquired
pneumonia), and/or (3) antimicrobial prescribed that had no
in vitro activity against the suspected or isolated pathogen for
the treatment of the infection. Consultation with the ID service
was independent of the AUT and was readily available at the
hospital; ID service consultation could be requested by all in-
ternal medicine teams.
Address reprint requests to Henry M. Blumberg, MD, Emory University
School of Medicine, Div of Infectious Diseases, 49 Jesse Hill Dr, Atlanta, GA
30303 (henry.m.blumberg@emory.edu).
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